Aesthetic clinic operator M1 Kliniken H1 revenue falls as HAEMATO Pharm disposal cuts trading sales
Aesthetic clinic operator M1 Kliniken H1 revenue falls as HAEMATO Pharm disposal cuts trading sales
Overview
Germany aesthetic medicine provider's Beauty segment H1 revenue grew 11%, EBIT up 23.8% yr/yr
Group revenue fell sharply after trading business sale; results not fully comparable yr/yr
Company completed exit from trading segment, now focused on Beauty clinic expansion
Outlook
M1 Kliniken targets Beauty segment revenue of EUR 200-300 mln by 2029
Company aims for a sustainable EBIT margin of at least 20% in Beauty segment
M1 Kliniken plans to expand national and international clinics to drive growth
Result Drivers
EFFICIENCY GAINS - Co said improved operating processes supported Beauty segment performance
MEDICAL CAPACITY EXPANSION - Targeted expansion of medical capacity contributed to Beauty segment growth
TRADING SEGMENT EXIT - Sharp decline in trading business results due to sale of HAEMATO Pharm GmbH and exit from trading segment
Company press release: ID:nEQc5LG3sa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| EUR 76.60 mln |
|
H1 EBIT |
| EUR 15.60 mln |
|
H1 EBITDA |
| EUR 17.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for M1 Kliniken AG is €29.00, about 43.2% above its September 8 closing price of €20.25
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Sept 7 - Audi introduces new compact EV in bid to boost European sales
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on M1 Kliniken AG
See all newsAesthetic clinic operator M1 Kliniken H1 revenue falls as HAEMATO Pharm disposal cuts trading sales
Brief: M1 Kliniken H1 Revenue EUR 76.6 Million
Brief: M1 Kliniken Says Co Sells Haemato Pharm Unit To Phoenix Group
Brief: M1 Kliniken H1 Revenue EUR 183.5 Million
Brief: M1 Kliniken Q1 Revenue EUR 92.7 Million